Intravenous gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. It may help visualize and detect vascular abnormalities in the blood brain barrier (BBB) and central nervous system (CNS).
In patients with impaired renal function, gadolinium based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF). A physician should be contacted if symptoms of NSF are encountered, such as dark or red patches on the skin; stiffness in joints; trouble moving, bending or straightening arms, hands, legs or feet; burning, itching, swelling, scaling, hardening and tightening of skin; pain in hip bones or ribs; or muscle weakness.
Common adverse reactions that may be experienced include headache, nausea, feeling hot, abnormal taste, and warmth, burning or pain local to the injection site.
General precautions should be taken in patients who are pregnant or breastfeeding, or who have a history of allergic reaction to contrast media, bronchial asthma or an allergic respiratory disorder.
Gadobutrol is indicated for use with magnetic resonance imaging for the following diagnostic processes:
AKH hospital, Wien, Austria
Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
University of California, San Francisco, San Francisco, California, United States
Piramal Diagnostic- Jankharia Imaging, Mumbai, Maharashtra, India
Universitätsklinikum Erlangen, Erlangen, Bayern, Germany
LMU Klinikum der Universität München - Großhadern, München, Bayern, Germany
Seoul National University Hospital, Seoul, Korea, Republic of
University of South Florida, Tampa, Florida, United States
Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.